glp-1/gip + b12 Tirzepatide Weight Loss · GLP-1 Treatments

A series of large-scale randomized controlled trials (RCTs) demonstrated that SGLT2i use reduced the risk of kidney disease progression in patients with and without diabetes ( post hoc analysis of SUSTAIN6 and PIONEER6 demonstrated that semaglutide slowed the eGFR decline in T2D patients with a high risk of CVD ( With combination therapy of SGLT2i and GLP1Ra, the preceding drug did not affect the renal outcome in the main analysis of RECAP study ( post hoc analysis, the SGLT2i-preceding group had a slower rate of eGFR decline in comparison to the GLP1Ra-preceding group, and multiple regression analysis identified the preceding of SGLT2i as an independent and significant factor of change in eGFR decline

Freitas LAA, Radis-Baptista G

Asandra gathers every piece of relevant information from a patient before they enter into a treatment plan

Metabolites produced by gut bacteria, such as LPS, have been implicated in affecting NIS functionality, thereby impacting iodine availability for thyroid hormone production

Compounded versions are not FDA-approved and now sit in a narrow legal space